Ocular Drug Delivery: Nanotechnology, Physical and Chemical Methods, Vitreous Drug Binding, and Aging Eye.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Journal of Ocular Pharmacology and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1089/jop.2018.0138PMID 31259643PMCID PMC6791467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trading Bankruptcy for Health: A Discrete-Choice Experiment.

  2018cited by this paper
• Binding of Small Molecule Drugs to Porcine Vitreous Humor.

  2018cited by this paper
• Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India

  2017cited by this paper
• Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics.

  2017cited by this paper
• Basic principles and current status of transcorneal and transscleral iontophoresis

  2017cited by this paper
• Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery

  2017cited by this paper
• Automated analysis of connected speech reveals early biomarkers of Parkinson’s disease in patients with rapid eye movement sleep behaviour disorder

  2017cited by this paper
• Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains

  2017cited by this paper
• Ultrasound-mediated ocular delivery of therapeutic agents: a review

  2017cited by this paper
• Ophthalmic gels: Past, present and future

  2017cited by this paper
• Trials and tribulations of skin iontophoresis in therapeutics

  2014cited by this paper
• Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.

  2013cited by this paper
• Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

  2013cited by this paper
• The Vitreous Humor As a Barrier to Nanoparticle Distribution

  2013cited by this paper
• Sustained in vivo release from imprinted therapeutic contact lenses.

  2012cited by this paper
• Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.

  2012cited by this paper
• Simulating Intravitreal Injections in Anatomically Accurate Models for Rabbit, Monkey, and Human Eyes

  2012cited by this paper
• A brief overview of electroporation pulse strength-duration space: a region where additional intracellular effects are expected.

  2012cited by this paper
• Compilation of 222 drugs' plasma protein binding data and guidance for study designs.

  2012cited by this paper
• Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles.

  2011cited by this paper
• Recent advances in ophthalmic drug delivery.

  2010cited by this paper
• Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV

  2009cited by this paper
• Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review.

  2008cited by this paper
• Personalized medicine: the translation of genetic knowledge to eye care.

  2008cited by this paper
• Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

  2008cited by this paper
• Ophthalmic light sensitive nanocarrier systems.

  2008cited by this paper
• Iontophoresis: a non-invasive ocular drug delivery.

  2006cited by this paper
• QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation.

  2006cited by this paper
• Ocular release of timolol from molecularly imprinted soft contact lenses.

  2005cited by this paper
• Age-related changes in human vitreous structure

  2005cited by this paper
• The promise and challenges of personalized medicine for eye diseases

  2004cited by this paper
• Drug Distribution in the Vitreous Humor of the Human Eye: The Effects of Aphakia and Changes in Retinal Permeability and Vitreous Diffusivity

  1997cited by this paper
• Compliance Aids — Do They Work?

  1992cited by this paper
• Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.

  1991cited by this paper
• Human vitreous fibres and vitreoretinal disease.

  1985cited by this paper

• Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?

  2022cites this paper
• Advanced nanodelivery platforms for topical ophthalmic drug delivery.

  2021cites this paper
• Dexamethasone Conjugates: Synthetic Approaches and Medical Prospects

  2021cites this paper
• Patient preferences in retinal drug delivery

  2021cites this paper
• Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives

  2020cites this paper
• Dual-acting therapeutic proteins for intraocular use.

  2020cites this paper